European Global Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European Global Times.

Press releases published on November 4, 2026

Nov. 4, 2026

Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition

Indeterminate GlobeNewswire

Nov. 4, 2026

Secura Bio Announces Two Duvelisib Presentations on Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma at the 2026 American Society of Hematology Annual Meeting

Indeterminate GlobeNewswire

Nov. 4, 2026

Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026

Indeterminate GlobeNewswire

Nov. 4, 2026

CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition

Indeterminate GlobeNewswire

Nov. 4, 2026

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

Indeterminate GlobeNewswire

Nov. 4, 2026

New Study Finds Nearly Half of Women Seeking Help for Menstrual Symptoms Say Their Concerns Were Dismissed

Indeterminate GlobeNewswire

Nov. 4, 2026

Codere Online to Release Financial Results for the Third Quarter 2026 on November 12th

Indeterminate GlobeNewswire

Nov. 4, 2026

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Indeterminate GlobeNewswire

Nov. 4, 2026

Adthena Report Shows ChatGPT Ads Surged to More Than 200,000 Placements Ahead of First AI-Driven Holiday Season

Indeterminate GlobeNewswire

Nov. 4, 2026

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

Indeterminate GlobeNewswire

Nov. 4, 2026

Terra Innovatum Achieves Key NRC Licensing Milestone, Delivers All 18 SOLO™ PSAR Chapters for Readiness Review as it Advances Toward 2027 First Reactor Deployment

Indeterminate GlobeNewswire

Nov. 4, 2026

Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights

Indeterminate GlobeNewswire

Nov. 4, 2026

WeShop to Present at A.G.P.’s Virtual Consumer Showcase on November 11-12, 2026

Indeterminate GlobeNewswire

Nov. 4, 2026

Aprea Therapeutics Announces Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Nov. 4, 2026

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

Indeterminate GlobeNewswire

Nov. 4, 2026

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

Indeterminate GlobeNewswire

Nov. 4, 2026

Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London

Indeterminate GlobeNewswire

Nov. 4, 2026

NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments

Indeterminate GlobeNewswire

Nov. 4, 2026

Processa Pharmaceuticals Announces Key Leadership Appointments

Indeterminate GlobeNewswire

Nov. 4, 2026

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

Indeterminate GlobeNewswire